Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

计划入组 8 人 · 首次发布于 2026 年 2 月 12 日

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

计划入组 85 人 · 首次发布于 2023 年 4 月 25 日

A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects

计划入组 20 人 · 首次发布于 2015 年 10 月 29 日

CWG-940

TAK-940

WD-940

KAOHSIUNG MEDICAL UNIVERSITY

Taiwan

Spanish Breast Cancer Research Group

Spain

Actio Biosciences, Inc.

United States

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

Boundless Bio Prioritizes BBI-355 and New ecDTx Program, Discontinues BBI-825 Development

Ionis and Ono Forge $940 Million Deal for Sapablursen in Polycythemia Vera Treatment